Atezolizumab/Hyaluronidase-tqjs

Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance Reiterating 2025 Financial Guidance Ranges for Total Revenue of $1,150 - 1,225 million, Representing YOY Growth of 13% - 21%, Adjusted EBITDA of $755 - $805 million, Representing YOY Growth of 19% - 27% and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YOY Growth of 17% - 26%1 SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, provided an update on its recent corporate activities and reiterated its 2025 financial guidance. "I am excited to announce that the significant growth we achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology. Our 2024 royalty revenue exceeded guidance driven by continued strong growth of DARZALEX SC and Phesgo, with modest initial contribution from VYVGART Hytrulo resulting from growing adoption and use primarily from its first indication for generalized myasthenia gravis. These three products will continue to drive our 2025 royalty revenues, with VYVGART Hytrulo becoming the largest dollar growth contributor in 2025," said Dr. Helen Torley, president and chief executive officer of Halozyme. "I am also pleased that we achieved four additional, significant ENHANZE regulatory product and indication approvals in the U.S. and EU in 2024 for VYVGART Hytrulo for CIDP, Tecentriq Hybreza, Ocrevus Zunovo and Opdivo Qvantiq, positioning Halozyme for strong continued growth, post 2025, once coverage reimbursement and access are fully established," said Dr. Torley. "Our leadership position in rapid subcutaneous drug delivery and long-term growth was further fortified with five new ENHANZE nominations from argenx and ViiV and an extension of our ENHANZE patent in Europe out to 2029, with a similar patent submitted in the U.S. Our 2025 guidance reflects our confidence in continuing robust total revenue, royalty revenue, adjusted EBITDA and non-GAAP EPS growth," Dr. Torley concluded. Fourth Quarter and Recent Corporate Highlights: Reiterating 2025 financial guidance previously announced on January 8, 2025 including total revenue of $1,150 million to $1,225 million, representing year-over-year growth of 13% to 21%, adjusted EBITDA of $755 million to $805 million, representing year-over-year growth of 19% to 27% and non-GAAP diluted earnings per share of $4.95 to $5.35, representing year-over-year growth of 17% to 26%. In December 2024, Halozyme entered into an Accelerated Share Repurchase agreement to repurchase $250.0 million of its common stock under the $750 million approved program from February 2024. Fourth Quarter and Recent Partner Highlights: In February 2025, Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorization for a subcutaneous ("SC") formulation of RYBREVANT® (amivantamab) with ENHANZE® in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy. In December 2024, Bristol Myers Squibb announced the U.S Food and Drug Administration ("FDA") approved Opdivo® Qvantig (nivolumab and hyaluronidase-nvhy) with ENHANZE® for SC use in most previously approved adult, solid tumor IV Opdivo® (nivolumab) indications resulting in the recognition of a $20.0 million milestone payment, and in January 2025, Opdivo® Qvantig was made available to patients. In December 2024, argenx announced the Ministry of Health, Labour and Welfare ("MHLW") in Japan approved VYVDURA® for the treatment of patients with chronic inflammatory demyelinating polyneuropathy ("CIDP"). In December 2024, Takeda announced the MHLW in Japan approved HYQVIA® with ENHANZE for patients with agammaglobulinemia or hypogammaglobulinemia disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency or secondary immunodeficiency. In November 2024, Zai Lab Limited (argenx commercial partner for China) announced the National Medical Products Administration approved VYVGART® Hytrulo for the treatment of patients with CIDP. In November 2024, Janssen announced the submission of regulatory applications to the FDA and European Medicines Agency ("EMA") seeking approval of a new indication for DARZALEX FASPRO® in the U.S. and DARZALEX® SC in the EU as a monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma. In October 2024, argenx initiated two studies evaluating VYVGART® Hytrulo with ENHANZE®, a Phase 3 study for adult patients with ocular myasthenia gravis and a Phase 2 study for kidney transplant recipients with antibody mediated rejection. In October 2024, Janssen announced the European Commission approved DARZALEX® SC for the treatment of patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant in combination with bortezomib, lenalidomide and dexamethasone. Fourth Quarter and Full Year 2024 Financial Highlights: Revenue was $298.0 million, compared to $230.0 million in the fourth quarter of 2023. The 30% year-over-year increase was primarily driven by royalty revenue growth and higher revenues under collaborative agreements mainly due to the timing of milestones achieved. Revenue for the quarter included $170.4 million in royalties, an increase of 40% compared to $122.1 million in the fourth quarter of 2023, primarily attributable to increases in revenue of DARZALEX® SC, VYVGART® Hytrulo and Phesgo®. Total revenue for the full year was $1,015.3 million, compared to $829.3 million in 2023, representing 22% year-over-year growth. The increase was primarily driven by royalty revenue growth, higher revenues under collaborative agreements mainly due to the timing of milestones achieved and higher sales of our proprietary products. Cost of sales was $42.1 million, compared to $52.3 million in the fourth quarter of 2023. The decrease was primarily due to lower bulk rHuPH20 sales. Cost of sales for the full year was $159.4 million, compared to $192.4 million in 2023. The decrease was primarily due to lower bulk rHuPH20 and device sales, partially offset by higher proprietary product sales. Amortization of intangibles expense was $17.8 million, compared to $17.8 million in the fourth quarter of 2023. Amortization of intangibles expense for the full year was $71.0 million, compared to $73.8 million in 2023. The decrease was primarily due to an impairment charge of $2.5 million recognized in the prior year to fully impair the TLANDO® product rights intangible asset. Research and development expense was $20.4 million, compared to $21.3 million in the fourth quarter of 2023. Research and development expense for the full year was $79.0 million, compared to $76.4 million in 2023. The increase was primarily due to planned investments in ENHANZE® related to the development of our new high-yield rHuPH20 manufacturing processes. Selling, general and administrative expense was $42.2 million, compared to $37.6 million in the fourth quarter of 2023. The increase was primarily due to increased compensation expense and consulting and professional service fees. Selling, general and administrative expense for the full year was $154.3 million, compared to $149.2 million in 2023. The increase was primarily due to increased compensation expense and consulting and professional service fees, partially offset by planned reductions in commercial marketing expense. Operating income was $175.5 million, compared to $101.0 million in the fourth quarter of 2023. Operating income for the full year was $551.5 million, compared to $337.6 million in 2023. Net income was $137.0 million, compared to $85.4 million in the fourth quarter of 2023. Net income for the full year was $444.1 million, compared to $281.6 million in 2023. EBITDA was $195.8 million, compared to $121.7 million in the fourth quarter of 2023. Adjusted EBITDA was $195.8 million, compared to $121.7 million in the fourth quarter of 2023.1 EBITDA for the full year was $632.2 million, compared to EBITDA of $435.6 million in 2023. Adjusted EBITDA for the full year was $632.2 million, compared to $426.2 million in 2023.1 GAAP diluted earnings per share was $1.06, compared to $0.65 in the fourth quarter of 2023. Non-GAAP diluted earnings per share was $1.26, compared to $0.82 in the fourth quarter of 2023.1 GAAP diluted earnings per share for the full year was $3.43, compared to $2.10 in 2023. Non-GAAP diluted earnings per share for the full year was $4.23, compared to $2.77 in 2023.1 Cash, cash equivalents and marketable securities were $596.1 million on December 31, 2024, compared to $336.0 million on December 31, 2023. The increase was primarily a result of cash generated from operations. Financial Outlook for 2025 The Company is reiterating its financial guidance for 2025, which was initially provided on January 8, 2025. For the full year 2025, the Company expects: Total revenue of $1,150 million to $1,225 million, representing growth of 13% to 21% over 2024 total revenue, primarily driven by increases in royalty revenue and product sales from XYOSTED®. Revenue from royalties of $725 million to $750 million, representing growth of 27% to 31% over 2024. Adjusted EBITDA of $755 million to $805 million, representing growth of 19% to 27% over 2024. Non-GAAP diluted earnings per share of $4.95 to $5.35, representing growth of 17% to 26% over 2024. The Company's earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2025 Financial Guidance Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the fourth quarter and full year ended December 31, 2024 today, Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Note Regarding Use of Non-GAAP Financial Measures In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables contain certain non-GAAP financial measures. The Company reports earnings before interest, taxes, depreciation, and amortization ("EBITDA"), adjusted EBITDA, Non-GAAP diluted earnings per share, Non-GAAP diluted shares, and guidance with respect to those measures, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time changes, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, and certain adjustments to income tax expense. The Company calculates non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating non-GAAP diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges and transaction costs for business combinations. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the U.S. GAAP measures may be materially different than the non-GAAP measures. The Company evaluates other items of income and expense on an individual basis for potential inclusion in the calculation of Non-GAAP financial measures and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company's normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These non-GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures, and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. The Company considers these non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company's core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's financial performance (including the Company's expected financial outlook for 2025) and expectations for future growth, profitability, total revenue, royalty revenue, EBITDA, Adjusted EBITDA, and non-GAAP diluted earnings-per-share and potential share repurchases under its share repurchase program. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and the expected expiration date of our ENHANZE® patent in Europe. Forward-looking statements regarding the Company's business may include potential growth and receipt of royalty and milestone payments driven by our partners' development and commercialization efforts, potential new clinical trial study starts and clinical data, regulatory submissions and product launches, the size and growth prospects of our partners' drug franchises, potential new or expanded collaborations and collaborative targets and regulatory review, and potential approvals of new partnered or proprietary products, and the potential timing of these events. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected delays in the execution of the Company's share repurchase program, unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of the Company's partnered or proprietary products, regulatory approval requirements, unexpected termination of the European ENHANZE® patent prior to the date of expiration, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] Footnotes: 1. Reconciliations between GAAP reported and non-GAAP financial information for actual results are provided at the end. SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

iStock/ OlekStock Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming particularly in the oncology and neurosciences spaces. The FDA approved 55 novel medicines in 2024—some first-in-class and others representing the first new mechanism of action for an indication in decades. Novel approvals last year ran the therapeutic gamut from cardiovascular and hematological to infectious diseases, with some of the most significant new mechanisms of action found in oncology and neuroscience. Top of mind is Bristol Myers Squibb’s Cobenfy, which the FDA greenlit in September as the first novel schizophrenia treatment in 35 years. Going back to February, we saw the approval of Iovance’s Amtagvi, the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi is indicated for advanced melanoma, which has been notoriously difficult to treat. Another notable milestone was the March approval of Madrigal Pharmaceuticals’ Rezdiffra, the first therapy to get the FDA’s nod for metabolic dysfunction-associated steatohepatitis (MASH). Here’s a look at five of the year’s most notable novel approvals. Iovance’s Amtagvi Jumpstarts TIL Space In February 2024, the FDA granted accelerated approval to Iovance Biotherapeutics for Amtagvi to treat patients with advanced melanoma. Forty years in the making, TIL therapies take advantage of the patient’s own immune cells—lymphocytes—which tend to be suppressed in the tumor environment. These cells are extracted from tumor biopsies, expanded in numbers or revamped for better efficacy, then transfused back into the patient, leading to antitumor activity. Iovance supported its Biologics License Application for Amtagvi with clinical data showing a 31% objective response rate with a median duration of response not reached at 18.6 months of follow-up; 42% of responses lasted for two years or longer. While CAR T therapies have transformed treatment for blood cancers, their performance hasn’t been as impressive against solid tumors. Part of the attraction of TIL therapies is their ability to recognize multiple antigens simultaneously, something CAR Ts are unable to do. Conventional CAR Ts can only recognize a small number of proteins on the surface of tumor cells, while TILs can identify tumor targets derived from intra- or extracellular tumor proteins, Sammy Farah, CEO of Turnstone Biologics, told BioSpace in February. Because solid tumors are known to be heterogeneous, TILs are likely to be successful as a treatment modality, Farah said. With more than 75 TIL immunotherapies in preclinical or clinical studies for various indications, numerous players are coming up behind Iovance. Turnstone Biologics is developing TIL therapies for colorectal cancers, head and neck squamous cell carcinoma and uveal melanoma, while Instil Bio is working on TILs for non-small cell lung cancer and other solid tumors. Bristol Myers Squibb and Incyte Corporation are also active in this space. Adaptimmune’s Tecelra Succeeds Against Synovial Sarcoma Also in the cell therapy space, Adaptimmune Therapeutics in August 2024 secured FDA approval for the first engineered T cell therapy for solid tumor cancers in the U.S. Tecelra is also the first new therapeutic option for synovial sarcoma—a rare soft tissue cancer—in more than 10 years. Like Amtagvi, Tecelra was approved under the FDA’s accelerated pathway. Also similar to Amtagvi, Tecelra leverages the patient’s immune cells and modifies them to be able to target cancer cells. Tecelra is specifically designed to recognize and attack the melanoma-associated antigen A4 (MAGE-A4) protein, which is crucial to preventing cell cycle arrest and cell death. MAGE-A4 is commonly overexpressed in solid tumors , especially synovial sarcoma. The FDA’s approval was based on results of the SPEARHEAD-1 study, in which treatment with Tecelra led to an overall response rate of 43%. A complete response was reported in 4.5% of patients. Treatment response lasted for at least 12 months in 39% of study participants who were responsive to the therapy. Bristol Myers Squibb’s Cobenfy Breaks Through Against Schizophrenia On the neuro front was the FDA’s approval of Bristol Myers Squibb’s Cobenfy in September. A first-in-class muscarinic agonist, Cobenfy comprises two separate drugs with distinct mechanisms of action: xanomeline activates M1 and M4 muscarinic receptors to reduce schizophrenia symptoms, while trospium reduces potential side effects of such activation, such as cardiovascular issues and increased production of saliva and tears. Dopamine-based drugs come with side effects such as weight gain and drowsiness. Targeting the muscarinic pathway may avoid such issues because these receptors are not expressed in key brain regions, Carlos Dortrait, SVP and general manager of U.S. immunology and neuroscience at BMS, told BioSpace in September. BMS supported Cobenfy’s application with data from three registrational studies. EMERGENT-1 and EMERGENT-2 established the drug’s efficacy in treating schizophrenia on the Positive and Negative Syndrome Scale, and EMERGENT-3 showed that the therapy, then called KarXT, could significantly reduce overall symptom severity. While Cobenfy proved the potential of targeting the muscarinic pathway in schizophrenia, the mechanism was called into question not two months later when AbbVie’s emraclidine failed to show efficacy in two Phase II clinical trials for the neuropsychiatric disease. The difference might lay in the M1 receptor, Stifel analysts suggested in November. While Cobenfy acts on both the M1 and M4 receptors, emraclidine only targets M4. “There’s been a longstanding thesis that M1 may contribute to efficacy on cognition,” the analysts wrote. If true, this would be bad news for Neurocrine Biosciences, which is developing a muscarinic M4 selective agonist, NBI-1117568. The San Diego–based company announced results from a mid-stage trial of the candidate in August 2024, showing that the lowest dose of NBI-1117568 improved symptoms of schizophrenia. All other doses failed to meet the study’s primary endpoint. Roche’s Tecentriq Hybreza Provides Flexible Treatment Option Also in September, the FDA greenlit the first subcutaneous PD-(L)1 blocker in the U.S., Roche’s Tecentriq Hybreza. Approved for the same indications as intravenous Tecentriq—including skin, liver, lung and soft-tissue cancers—the subcutaneous formulation leverages Halozyme Therapeutics’ Enhanze technology , which uses a recombinant enzyme to digest hyaluronan proteins beneath the skin to improve fluid flow in the subcutaneous space. This effect allows large volumes of the liquid Tecentriq to be injected under the skin, while also boosting the medicine’s dispersion and absorption. Tecentriq Hybreza “can treat patients faster and in more accessible settings” and “offers patients with multiple cancer types and their physicians greater flexibility and choice of treatment administration,” Roche CMO Levi Garraway said in a statement following the approval. The subcutaneous formulation is administered in approximately seven minutes, while an intravenous infusion of Tecentriq usually takes 30 minutes to 60 minutes, according to Roche. Approval of Tecentriq Hybreza was based partly on the Phase Ib/III IMscin001 study, in which the subcutaneous injection reached comparable levels of the drug in the blood as its intravenous formulation, with similar safety and efficacy pro ARS Pharmaceuticals’ Neffy First Nasal Spray for Severe Allergies People living with severe allergic reactions that could lead to anaphylaxis got a new, more palatable treatment option in August when the FDA approved ARS Pharmaceuticals’ Neffy as the first nasal spray for the condition. The first epinephrine product for the treatment of anaphylaxis that is not administered by injection, Neffy is a single-dose nasal spray administered into one nostril. A second dose may be administered if there is no improvement in symptoms or symptoms worsen, according to the FDA’s approval announcement. “Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections,” Kelly Stone, associate director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in a statement. “The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis.” Neffy’s approval was supported by four studies in 175 healthy adults without anaphylaxis, which showed comparable epinephrine blood concentrations between the nasal spray and approved epinephrine injection products. Neffy also led to similar increases in blood pressure and heart rate as epinephrine injection products did. These physiological changes are critical effects of epinephrine in the treatment of anaphylaxis, according to the FDA.